February 27, 2019

The Michigan Alzheimer’s Disease Center has invited Dr. Gil Rabinovici, to present at Neurology Grand Rounds, Wednesday, February 27th, 2019

10:30 AM to 11:30 AM

Danto Auditorium, 2nd floor of the CVC (Samuel and Jean Frankel Cardiovascular Center)

"Heterogeneity in Alzheimer’s Disease: Insights from Amyloid and Tau PET"

Dr. Rabinovici’s research investigates how structural, functional and molecular brain imaging techniques can be used to improve diagnostic accuracy in dementia and to study the biology of neurodegenerative diseases, with the goal of accelerating treatment development. He leads the MAC PET imaging program and is Associate Director of the UCSF Alzheimer’s Disease Center. Dr. Rabinovici is principal investigator of Imaging Dementia: Evidence for Amyloid Scanning (IDEAS), a U.S.-wide study to assess the clinical utility of amyloid PET in 18,500 patients with MCI/dementia of uncertain etiology. He is co-PI and PET Core Director of the multi-site Longitudinal Evaluation of Early-Onset Alzheimer’s Disease Study (LEADS).

Gil Rabinovici, MD

Professor of Neurology, UCSF Memory & Aging Center
Edward Fein and Pearl Landrith Endowed Professor in Memory & Aging
Professor in Residence of Radiology and Biomedical Imaging

Dr. Rabinovici is the Edward Fein and Pearl Landrith Endowed Professor in Memory & Aging. He received his BS degree from Stanford University and MD from Northwestern University Medical School. He completed an internship in internal medicine at Stanford University, neurology residency (and chief residency) at UCSF and a behavioral neurology fellowship at the Memory and Aging Center (MAC).

Dr. Rabinovici participates in patient evaluations and management. On the research front, he leads the MAC PET imaging program, is principal investigator of a cohort study of early-onset Alzheimer’s disease and of Imaging Dementia: Evidence for Amyloid Scanning (IDEAS), a U.S.-wide study sponsored by the Centers for Medicare and Medicaid Services to assess the clinical utility of amyloid PET in 18,500 Medicare beneficiaries. His work investigates how structural, functional and molecular brain imaging techniques can be used to improve diagnostic accuracy in dementia and to study the biology of neurodegenerative diseases, with the goal of accelerating treatment development.

Dr. Rabinovici’s work is supported by the National Institutes of Health, the Alzheimer’s Association, the American College of Radiology, the Michael J. Fox Foundation, the Tau Consortium, the Association for Frontotemporal Lobar Degeneration and industry partners. Awards recognizing his work include the 2015 Christopher Clark Award for Advancement of the Field of Amyloid Imaging, the 2012 American Academy of Neurology Research Award in Geriatric Neurology and the 2010 Best Paper in Alzheimer’s Disease Neuroimaging: New Investigator Award from the Alzheimer’s Association.